CMS Opened the Door for Cannabinoids. ACOs Still Need the Operating Model

When CMS launched the Substance Access Beneficiary Engagement Incentive, it created a meaningful new pathway for eligible hemp-derived cannabinoid products inside select Medicare models.

For the hemp and cannabis industry, that development is easy to understand as a market access moment. A federal healthcare pathway for cannabinoid products represents a major shift in how the category may be viewed by physicians, healthcare organizations, and policymakers.

But the real significance of the program becomes clearer when viewed from the perspective of an Accountable Care Organization.

An ACO is responsible for improving outcomes while managing the total cost of care for a defined Medicare population. Every new intervention has to be evaluated through that lens. Can it be used safely? Can physicians defend the recommendation? Can patients understand and follow the care plan? Can outcomes be measured? Can the organization determine whether the intervention is helping reduce avoidable downstream cost?

That is where implementation becomes the central issue.

CMS has created the framework. ACOs now need a practical operating model.

The Program Begins With Clinical Workflow

For an ACO, cannabinoid access begins as a workflow question.

Before a product can be meaningfully evaluated, the organization has to understand how the program would function inside patient care. The ACO has to define which patients may be appropriate, how physicians will evaluate those patients, how shared decision-making will be documented, how medication interactions will be reviewed, how products will be tracked, how patients will be monitored, and how outcomes will be reported.

These are the practical details that turn policy into healthcare delivery.

A product may meet baseline CMS eligibility requirements, but healthcare adoption depends on the care model around it. In a Medicare setting, the product sits inside a system of documentation, oversight, patient education, follow-up, safety monitoring, and outcome measurement.

That system is what gives the intervention clinical credibility.

Product Eligibility Is the Entry Point

The CMS product requirements are important. Eligible products need to satisfy the program’s criteria, including THC limits, appropriate product format, testing, and documentation.

Those requirements create the entry point.

The adoption decision will depend on a broader set of considerations. ACOs will want to understand the clinical rationale for use, the patient population most likely to benefit, the available safety data, the evidence supporting the dose, the risks that should be discussed with patients, and the outcomes that should be measured over time.

This matters because the BEI program serves Medicare populations that often include older adults with complex medication profiles, chronic conditions, and elevated risk from poor sleep, pain, anxiety, polypharmacy, falls, and avoidable utilization.

For an ACO, a cannabinoid product has to fit inside a responsible clinical pathway.

That pathway has to make sense to physicians, patients, administrators, and compliance teams.

The Implementation Gap

The BEI program brings together groups that have historically operated in separate worlds.

Cannabinoid companies understand formulation, supply, quality, and commercialization. Physicians understand clinical judgment, patient risk, and medical documentation. ACOs understand population health, utilization, and total cost of care.

The challenge is connecting those worlds into one functioning care model.

That requires infrastructure for physician education, patient intake, eligibility screening, medication review, shared decision-making, product tracking, patient monitoring, outcomes collection, adverse-event reporting, and data export.

For many ACOs, building that infrastructure internally would require meaningful time and resources. Existing EHRs can capture parts of the care journey, but cannabinoid-specific workflows, product traceability, structured shared decision-making, and real-world evidence collection may require additional support.

That is the implementation gap.

Why Cannabinoid Care Needs a Clinical Operating Layer

For cannabinoid products to move responsibly into healthcare settings, the industry needs a clinical operating layer that connects product access to structured care.

That means physician education, patient intake, medication review, shared decision-making, treatment oversight, safety monitoring, documentation, and outcomes collection. These are the systems that allow an ACO to move from interest in cannabinoids to a program that can be managed, reviewed, and evaluated.

Lidera Health is the only platform I am currently aware of that is purpose-built around this challenge. I recently invested in and joined the board because I believe this type of infrastructure will be essential for the BEI program to succeed and for cannabinoids to move responsibly into broader clinical care settings.

The importance of this platform extends beyond software. For physicians, it supports education, decision-making, documentation, and follow-up. For patients, it creates a clearer and more guided care experience. For ACOs, it provides a structured way to implement the program, track the intervention, collect outcomes, and evaluate whether the care pathway is producing value.

Read more: The Scratch-Off Comes to Cannabis Retail: Last Week in Weed June 9-June 15, 2026 – Cannabis & Tech Today

Real-World Evidence Is the Long-Term Value

The BEI program should also be understood as an evidence-generation opportunity.

The long-term value of the program will depend on whether participating organizations can answer the questions that matter most.

Which patients benefited? Which products were used? At what dose? For which indication? With what safety profile? What changed over time? Did utilization patterns improve? Did medication use change? Did the intervention support the total cost-of-care goals of the model?

Those questions require structured data.

A well-designed implementation model can capture patient eligibility, baseline clinical status, shared decision-making, product identification, dose, outcomes, adverse events, adherence, and healthcare utilization over time.

That is how cannabinoid access becomes real-world evidence.

And real-world evidence is what can help physicians, ACOs, CMS, and the broader healthcare system understand where these products belong.

Physician Confidence Will Shape Adoption

Physicians will play a central role in whether the program succeeds.

A physician recommending a cannabinoid product inside a Medicare care model needs confidence in both the product and the process around it. They need to understand the active ingredient, the dose, the evidence base, the safety profile, the appropriate patient population, the medication interaction considerations, and the monitoring plan.

They also need the recommendation to be documented in a way that stands up to clinical review.

This is especially important in senior care. Many patients are taking multiple medications. Many have chronic conditions. Many may also have concerns or confusion about the difference between intoxicating THC products and non-intoxicating cannabinoids.

Physician confidence depends on clarity.

The more structured the pathway, the easier it becomes for a physician to make an informed recommendation and for the care team to support the patient after that recommendation is made.

Patient Understanding Is Part of the Clinical Model

Patient experience will also determine the quality of the evidence generated.

A patient who understands why a product was recommended, how to use it, what to expect, and when to report concerns is more likely to follow the care plan. A patient who feels confused, concerned, or unsupported is more likely to discontinue.

Adherence matters because outcomes depend on use.

Education, follow-up, and monitoring are therefore part of the clinical model. They help protect patients, support physicians, and improve the reliability of the evidence generated by the program.

This is one of the reasons implementation infrastructure matters so much. The program has to work for patients in the real world, across diverse care settings, with different levels of familiarity and comfort around cannabinoid products.

Where TruCBN Fits

At FloraWorks, we built TruCBN for the healthcare and regulatory standards we believed this category would eventually need to meet.

The BEI program is the first federal framework where that alignment becomes visible.

TruCBN is a standardized cannabinol ingredient supported by a clinical and safety data package focused on sleep. Sleep is one of the clearest use cases for this type of program because poor sleep in older adults can contribute to downstream issues that matter deeply to Medicare organizations, including impaired cognition, sedating medication use, falls, hospitalizations, and overall higher healthcare utilization.

A standardized, clinically supported, non-intoxicating cannabinoid ingredient helps answer one part of the equation: product readiness.

A platform like Lidera helps answer the next part: implementation readiness.

Together, those two pieces reflect where the category is heading. Healthcare organizations will need products with evidence, safety, and quality behind them. They will also need systems that allow those products to be integrated into care responsibly.

The Larger Lesson

The cannabis and hemp industry has spent years focused on access: access to licenses, retail channels, banking, distribution, consumers, and institutional legitimacy.

Healthcare access requires another layer.

It requires infrastructure that can earn physician confidence, support patient care, document clinical decision-making, monitor safety, measure outcomes, and generate evidence.

The BEI program makes that requirement visible.

The opportunity ahead is larger than supplying products into a new federal pathway. It is building the care infrastructure that allows cannabinoid products to be used responsibly, measured credibly, and evaluated within the healthcare system.

CMS has opened the door.

The next step is helping healthcare walk through it.